OSLO, Norway--(BUSINESS WIRE)--Nordic Nanovector is pleased to announce that the Japan Patent Office (JPO) has issued patent no. 5646652 entitled “NOVEL RADIOIMMUNOCONJUGATES AND USES THEREOF.” The issued claims cover Nordic Nanovector’s proprietary radioimmunotherapy (RIT) technology, including the company`s lead product candidate Betalutin™, a new targeted agent for the treatment of relapsed B-cell non-Hodgkin lymphoma (NHL).
Help employers find you! Check out all the jobs and post your resume.
